CARDIOFLOW-B: Letter to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
CARDIOFLOW-B: Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
CARDIOFLOW-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
CARDIOFLOW-B: ESTIMATED INTERIM RESULTS FOR THE SIX MONTHS ENDEDJUNE 30, 2024 AND BUSINESS UPDATE
CARDIOFLOW-B: SIXTH AMENDED AND RESTATEDMEMORANDUM AND ARTICLES OF ASSOCIATION
CARDIOFLOW-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
CARDIOFLOW-B: FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 26, 2024
CARDIOFLOW-B: VOLUNTARY ANNOUNCEMENT - ALTAVALVE WAS GRANTED THE BREAKTHROUGH DEVICE DESIGNATION BY THE FDA
CARDIOFLOW-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
CARDIOFLOW-B: VOLUNTARY ANNOUNCEMENT - CE MARK APPROVAL OF VITAFLOW LIBERTY
CARDIOFLOW-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
CARDIOFLOW-B: PROPOSED AMENDMENTS TO THE MEMORANDUM ANDARTICLES OF ASSOCIATION
CARDIOFLOW-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
CARDIOFLOW-B: ESTIMATED ANNUAL RESULTS FOR THE YEAR 2023 AND BUSINESS UPDATE
CARDIOFLOW-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
CARDIOFLOW-B: VOLUNTARY ANNOUNCEMENT -NMPA APPROVAL FOR REGISTRATION APPLICATION OFANCHORMAN LAAC SYSTEM
CARDIOFLOW-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
CARDIOFLOW-B: NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS
CARDIOFLOW-B: NOTIFICATION LETTER AND REQUEST FORM TO REGISTERED SHAREHOLDERS
CARDIOFLOW-B: FORM OF PROXY FOR USE AT THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, DECEMBER 29, 2023
No Data